Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Biologic therapy.

University of Bologna, Bologna, Italy.

Survival: monthsCountry:Italy
Toxiciy Grade:5City/State/Province:Bologna
Treatments:Biologic therapyHospital:University of Bologna
Drugs:Journal:Link
Date:Oct 2012

Description:

Patients:
This phase 3 study involved follicular lymphoma patients who were divided into two separate treatment groups. Group A consisted of 103 patients with a median age of 61 years and 51% male. Group B consisted of 98 patients with a median age of 60 years and 43% male.

Treatment:
Patients in group A were treated with the biologic therapy agents bortezomib (a proteasome inhibitor) and rituximab (a monoclonal antibody for CD20 that causes the immune system to attack tumor cells).

Patients in group B were treated with rituximab only.

Toxicities:
There were two treatment-related deaths in group A due to septic shock and pneumonia. Grade 3 or higher diarrhea, neutropenia, and infection were also reported.

There was one treatment-related death in group B due to meningitis. Grade 3 or higher infection, neutropenia, and anemia were also reported.

Results:
The median overall survival rates for groups A and B were 37.8 and 41.5 months, respectively.

Support:
This study was supported by Johnson & Johnson Pharmaceutical Research & Development and Millennium Pharmaceuticals, Inc.

Correspondence: Dr. Pier Luigi Zinzani; email: [email protected]



Back